Daniel Lubin

Daniel Lubin

Auto-generated profile, based on publicly available information

Daniel Lubin

Winship Cancer Institute Emory University Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2018 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
DLDaniel Lubin
Daniel Lubin
EBEzra Baraban
Ezra Baraban
ALAmanda Lisby
Amanda Lisby
SJSahar Jalali-Farahani
Sahar Jalali-Farahani
PZPaul Zhang
Paul Zhang
VLVirginia Livolsi
Virginia Livolsi

1 February 2024 in Thyroid®
Verified
Journal Article
Closed access
BXBin Xu
Bin Xu
KVKartik Viswanathan
Kartik Viswanathan
MAMahsa S. Ahadi
Mahsa S. Ahadi
SASara Ahmadi
Sara Ahmadi
BABayan A Alzumaili
Bayan A Alzumaili
IGIan Ganly
Ian Ganly
Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) needs to be clarified. Experimental design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germline mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients respectively. RETM918T was the most common somatic RET mutation (n=75). RET somatic mutations were associated with male sex, larger tumor size, advanced AJCC stage, vascular invasion (VI), and high IMTCGS grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (8th edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germline mutations were significantly associated with reduced distant metastasis free survival on univariate analysis but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germline mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall and disease-specific survival, independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage . RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased overall and disease-specific survival in MTC but its prognostic value needs to be confirmed in future studies.

6 December 2019 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
DLDaniel Lubin
Daniel Lubin
DBDarren Buonocore
Darren Buonocore
XWXiao‐Jun Wei
Xiao‐Jun Wei
JCJean‐Marc Cohen
Jean‐Marc Cohen
OLOscar Lin
Oscar Lin

1 July 2019 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
DLDaniel Lubin
Daniel Lubin
ETErik Toorens
Erik Toorens
PZPaul J. Zhang
Paul J. Zhang
SJShabnam Jaffer
Shabnam Jaffer
EBEzra Baraban
Ezra Baraban
ANAnupma Nayak
Anupma Nayak
Adenomyoepitheliomas (AME) of the breast and epithelial-myoepithelial carcinomas (EMCs) of salivary gland are morphologically similar tumors defined by the presence of a biphasic population of ductal epithelial elements mixed with myoepithelial cells. We sought to explore the molecular profile of AMEs and determine whether they might also share the PLAG1, HMGA2, and HRAS alterations seen in EMCs. Tumor tissue from 19 AMEs was sequenced and analyzed using Ion AmpliSeq Cancer Hotspot Panel v2 covering ∼2800 COSMIC mutations across 50 cancer-related genes. Cases were additionally screened by FISH for PLAG1 and HMGA2 rearrangements. Of 19 AMEs (12 benign; 7 malignant), 2 cases failed the DNA extraction. Of the remaining 17 cases, 14 had at least one nonsynonymous mutation identified. The most common mutations were in PIK3CA (6/17) and AKT1 (5/17), which were mutually exclusive. Two tumors demonstrated mutations in APC, while 1 demonstrated an STK11 mutation. Mutations in ATM, EGFR, FGFR3 or GNAS were identified in 4 cases with concurrent AKT1 mutations. HRAS mutation co-occurring with PIK3CA mutation was noted in 1 case of ER-negative malignant AME. While 2 cases harbored alterations in HMGA2, none was positive for PLAG1 rearrangement. Our findings confirm that breast AMEs are genetically heterogeneous exhibiting recurrent mutually exclusive mutations of PIK3CA and AKT1 in a majority of cases. HRAS mutations co-occur with PIK3CA mutations in ER-negative AMEs and may possibly be linked to clinically aggressive behavior. We identified hotspot mutations in additional genes (APC, STK11, ATM, EGFR, FGFR3, and GNAS). We report the presence of HMGA2 alterations in 2/16 AMEs, supporting their relationship with EMC of salivary glands in at least a subset of cases. PIK3CA, AKT1 and HRAS may serve as potential actionable therapeutic targets in clinically aggressive AMEs.

11 September 2021 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
KVKartik Viswanathan
Kartik Viswanathan
SBShaham Beg
Shaham Beg
BHBing He
Bing He
TZTaotao Zhang
Taotao Zhang
RCRichard Cantley
Richard Cantley
TSTheresa Scognamiglio
Theresa Scognamiglio
Objectives: Salivary gland acinic cell carcinoma (AciCC) has recognizable cytomorphologic features that can overlap with benign and malignant entities, creating a diagnostic challenge. AciCC harbors a t(4;9) translocation increasing nuclear receptor subfamily 4 group A member 3 (NR4A3) expression, detectable by immunohistochemistry (IHC) on surgical resection (SR). NR4A3 IHC cytology data are limited. Here, we examine NR4A3 IHC on smears, cell blocks (CBs), and SRs of AciCC and its mimickers. Methods: Our cohort comprised AciCC (including high-grade transformation), secretory carcinoma, mucoepidermoid carcinoma (MEC), Warthin tumor, pleomorphic adenoma (PA), cellular PA, carcinoma ex-PA, oncocytic carcinoma, oncocytoma, and nodular oncocytosis. NR4A3 IHC (Santa Cruz Biotechnology and Origene antibodies) was positive if more than 5% tumor cells showed nuclear staining. Results: Among CBs, 90% of AciCC cases and none of the mimickers expressed NR4A3. Among SRs, 100% of AciCC cases showed diffuse NR4A3, whereas one high-grade MEC expressed focal NR4A3. Concordance was 95% with two antibody clones. Sensitivity, specificity, positive predictive value, and negative predictive value were 90%, 100%, 100%, and 94.7% for CBs and 100%, 98.8%, 92.3%, and 100% for SRs, respectively. NR4A3 immunostaining was demonstrable on smears from an AciCC case. Conclusions: NR4A3 IHC can be a robust diagnostic tool to identify AciCC, especially for cytology specimens.

1 February 2018 in Human Pathology
Verified
Journal Article
Closed access
DLDaniel J. Lubin
Daniel J. Lubin
RMRosemarie Mick
Rosemarie Mick
SSStuti G. Shroff
Stuti G. Shroff
KSKristen Stashek
Kristen Stashek
EFEmma E. Furth
Emma E. Furth